This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Latest News
-
22nd October 2021
Arecor commentary in MedNous on how faster insulin can enable the artificial pancreas
-
11th October 2021
ARECOR’S POLYSACCHARIDE VACCINE PATENT UPHELD
-
20th September 2021
ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETES
News
-
22/10/2021
Arecor commentary in MedNous on how faster insulin can enable the artificial pancreas
-
11/10/2021
ARECOR’S POLYSACCHARIDE VACCINE PATENT UPHELD
-
20/09/2021
ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETES
-
09/09/2021
FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR AT247, AN ULTRA-RAPID INSULIN FOR THE TREATMENT OF DIABETES
-
07/09/2021
EXCLUSIVE FORMULATION COLLABORATION WITH INTAS PHARMACEUTICALS LTD
-
22/06/2021
ARECOR TO PRESENT AT BIOTRINITY 2021
-
10/06/2021
Arecor appoints Dr Lindsey Foulkes as Chief Operating Officer
-
07/06/2021
ARECOR ANNOUNCES EXCLUSIVE FORMULATION STUDY COLLABORATION WITH PAR
-
20/05/2021
ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH LILLY
-
13/05/2021
ARECOR GRANTED KEY US PATENT
-
31/03/2021
ARECOR RECEIVES £2.8 MILLION GRANT AWARD FROM INNOVATE UK